Search

Your search keyword '"Le Pen C"' showing total 300 results
Start Over Author "Le Pen C"
300 results on '"Le Pen C"'

3. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease

Author

Fraix, V, Houeto, J.-L., Lagrange, C., Le Pen, C., Krystkowiak, P., Guehl, D., Ardouin, C., Welter, M.-L., Maurel, F., Defebvre, L., Rougier, A., Benabid, A.-L., Mesnage, V., Ligier, M., Blond, S., Burbaud, P., Bioulac, B., Destee, A., Cornu, P., and Pollak, P.

Subjects
Parkinson's disease -- Care and treatment, Parkinson's disease -- Economic aspects, Neural stimulation -- Patient outcomes, Neural stimulation -- Economic aspects, Thalamus -- Research, Cost benefit analysis -- Research, Cost benefit analysis, Health, Psychology and mental health
Published
2006

9. T06.01.19 THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES

Author

Newsome, P., primary, Schattenberg, J., additional, Serfaty, L., additional, Aghemo, A., additional, Augustin, S., additional, Tsochatzis, E., additional, Canbay, A., additional, De Ledinghen, V., additional, Bugianesi, E., additional, Romero-Gomez, M., additional, Ryder, S., additional, Bente, H., additional, Boursier, J., additional, Petta, S., additional, Crespo, J., additional, Castera, L., additional, Leroy, V., additional, Le Pen, C., additional, Fricke, F., additional, Elliot, R., additional, Atella, V., additional, Mestri-Fernandez, J., additional, Floros, L., additional, Torbica, A., additional, Morgan, A., additional, Trylesinski, A., additional, Curie, S., additional, Stirzaker, E., additional, Vasudevan, S., additional, Pezzulo, L., additional, and Ratziu, V., additional

Published
2020
Full Text
View/download PDF

10. The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries

Author

Schattenberg, J, additional, Newsome, P, additional, Serfaty, L, additional, Aghemo, A, additional, Augustin, S, additional, Tsochatzis, E, additional, Canbay, A, additional, de Ledinghen, V, additional, Bugianesi, E, additional, Romero-Gomez, M, additional, Ryder, S, additional, Bantel, H, additional, Boursier, J, additional, Petta, S, additional, Crespo, J, additional, Castera, L, additional, Leroy, V, additional, Le Pen, C, additional, Fricke, F-U, additional, Elliott, R, additional, Atella, V, additional, Mestre-Ferrandiz, J, additional, Floros, L, additional, Torbica, A, additional, Morgan, A, additional, Hartmanis, S, additional, Trylesinki, A, additional, Cure, S, additional, Stirzaker, E, additional, Vasudevan, S, additional, Pezzulo, L, additional, and Ratziu, V, additional

Published
2020
Full Text
View/download PDF

11. The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries

Author

Newsome, P., primary, Schattenberg, J., additional, Serfaty, L., additional, Aghemo, A., additional, Augustin, S., additional, Tsochatzis, E., additional, Canbay, A., additional, Ledinghen, V.de, additional, Bugianesi, E., additional, Romero-Gomez, M., additional, Ryder, S., additional, Bantel, H., additional, Boursier, J., additional, Petta, S., additional, Crespo, Javier, additional, Castera, L., additional, Leroy, V., additional, Le Pen, C., additional, Fricke, F., additional, Elliott, R., additional, Atella, V., additional, Mestre-Ferrandiz, J., additional, Floros, Lefteris, additional, Torbica, A., additional, Morgan, A., additional, Hartmanis, S., additional, Trylesinki, A., additional, Cure, S., additional, Stirzaker, E., additional, Vasudevan, S., additional, Pezzulo, L., additional, and Ratziu, V., additional

Published
2020
Full Text
View/download PDF

14. PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

Author

Le Pen, C., primary, Fricke, F.U., additional, Newsome, P., additional, Schattenberg, J.M., additional, Serfaty, L., additional, Aghemo, A., additional, Augustin, S., additional, Tsochatzis, E., additional, Canbay, A., additional, de Lédinghen, V., additional, Bugianesi, E., additional, Romero-Gomez, M., additional, Ryder, S., additional, Bantel, H., additional, Boursier, J., additional, Petta, S., additional, Crespo, J., additional, Castera, L., additional, Leroy, V., additional, Elliott, R.A., additional, Atella, V., additional, Mestre-Ferrandiz, J., additional, Floros, L., additional, Torbica, A., additional, Morgan, A., additional, Hartmanis, S., additional, Trylesinski, A., additional, Cure, S., additional, Stirzaker, E., additional, Vasudevan, S., additional, Pezzullo, L., additional, and Ratziu, V., additional

Published
2019
Full Text
View/download PDF

31. [Medico-economic evaluation of abciximab]

Author

Le Pen C, julia bonastre, and Pinton P

Subjects
National Health Programs, Abciximab, Cost-Benefit Analysis, Myocardial Ischemia, Antibodies, Monoclonal, Anticoagulants, Survival Analysis, Disease-Free Survival, Drug Costs, Immunoglobulin Fab Fragments, Treatment Outcome, Risk Factors, Injections, Intravenous, Public Health Practice, Humans, France, Angioplasty, Balloon, Coronary, Infusions, Intravenous, Models, Econometric, Platelet Aggregation Inhibitors
Abstract

Abciximab (RéoPro) is a chimeric monoclonal antibody directed against platelet glycoprotein IIb-IIIa. It reduces the frequency of major cardiac ischaemic events after percutaneous transluminal coronary angioplasty (PTCA). This treatment is more expensive than the commonly used treatment (aspirin and heparin). However, a treatment can only be validly assessed in term of its cost-benefit ratio. The authors present the results of a medico-economic evaluation of abciximab in the French institutional context, based on the three-year clinical results of the EPIC study (Evaluation of abciximab for the Prevention of Ischemic Complications). The efficacy of treatment was expressed by means of two quantitative indicators: the number of patients with no major ischaemic event (MIE) and the number of years of life without myocardial infarction or revascularization. According to French good practice recommendations for economic evaluation of therapeutic strategies, major ischaemic events were assessed by using the complete cost of the corresponding homogeneous groups of diseases (GHM). Medico-economic evaluation of abciximab showed that the net excess cost per patient for national health insurance was 395 Francs, while the cost of the product is 5,300 Francs. The incremental cost per additional patient with no major ischaemic event is 6,585 Francs and the incremental cost per additional year of life without myocardial infarction or revascularization is 2,469 F. From a public health point of view, abciximab administered by bolus injection plus a 12-hour infusion, presents a good cost-effectiveness ratio in the prevention of cardiac ischaemic complications in high-risk patients after PTCA.

Published
2003

34. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France]

Author

Le Pen C, Herve Lilliu, Mp, Allicar, Olivier V, and Kj, Gregor

Subjects
Adult, Male, Patient Care Team, Psychiatric Status Rating Scales, National Health Programs, Cost-Benefit Analysis, Pirenzepine, Middle Aged, Benzodiazepines, Double-Blind Method, Olanzapine, Schizophrenia, Haloperidol, Humans, Female, France, Referral and Consultation, Antipsychotic Agents
Abstract

The purpose of this study is to provide an economic comparison of olanzapine-treated and haloperidol-treated patients from the subset of French patients who participated in a large, international, randomised clinical trial in schizophrenia.Patients were evaluated from randomisation until discontinuation, drop out or completion of the 52-week study. The primary clinical measure was "clinically important response" (derived from BPRS total scores). The secondary measure was "clinically important improvement" (derived from CGI severity of illness scores). The primary economic measure was mean per diem, per patient total direct medical costs.A total of 275 French patients where included in the study. Demographics and other baseline differences between olanzapine- and haloperidol-treated patients were not statistically significant. Olanzapine-treated patients (205 +/- 142 days) experienced significantly (p0.001) longer evaluation periods than haloperidol-treated patients (132 +/- 129 days). Olanzapine-treated patients (54%) were significantly (p = 0.03) more likely to experience a clinically important response than haloperidol-treated patients (40%). Olanzapine-treated patients (69%) were significantly (p = 0.02) more likely to experience clinically important improvement than haloperidol-treated patients (54%). The mean per diem, per patient total direct medical cost was statistically lower (p = 0.033) for olanzapine-treated patients (FF619 +/- 509) compared to haloperidol-treated patients (FF756 +/- 478).Olanzapine treatment was associated with significantly better clinical outcomes and per diem total direct medical cost than haloperidol treatment. The findings indicate that olanzapine is dominant compared to haloperidol for the treatment of schizophrenia, in the context of analysed data. These findings produce increased relevance in France to the existing evidence supporting olanzapine's cost and effectiveness profiles.

Published
1999

35. [Medical-economic models of benign prostatic hypertrophy]

Author

Le Pen C, Lukacs B, Rumeau-Pichon C, and julia bonastre

Subjects
Aged, 80 and over, Male, Prostatectomy, Clinical Trials as Topic, Finasteride, Age Factors, Prostatic Hyperplasia, Endoscopy, Middle Aged, Models, Theoretical, Urinary Retention, Markov Chains, Placebos, Life Expectancy, Acute Disease, Costs and Cost Analysis, Humans, Enzyme Inhibitors, Monte Carlo Method, Aged, Probability
Abstract

This article is designed to explain the importance of medico-economic models for evaluation of the impact of treatments of benign prostatic hyperplasia. The authors illustrate this approach by comparing two hypotheses: transurethral resection of the prostate versus watchful waiting using a Markov type of model. This model is able to simulate the probability of development of events such as transurethral resection of the prostate, acute urinary retention over a 40-year period by 3-month cycles. The model is also able to simulate the mean cost of management of a patient over this period. This type of model may appear slightly artificial and complicated, but it is the only model which could allow long-term simulations of the respective value of the various therapeutic strategies for BPH. This type of model is also evolutive, its performance is gradually improved as new data become available in the literature, allowing refinement of a number of hypotheses.

Published
1999

46. Impact médico-économique du docétaxel dans le traitement adjuvant du cancer du sein

Author

Miadi-Fargier, Houda, primary, Le Pen, C., additional, Guastalla, JP., additional, Pivot, Xavier, additional, Woronoff-Lemsi, Macha C., additional, Roché, H., additional, Pinguet, Frédéric, additional, Gligorov, J., additional, Debrix, I., additional, Spielmann, M., additional, Antoine, Éric Charles, additional, and de Pouvourville, Gérard, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results